Hyperactive Delirium with Severe Agitation.
Springer B.
Emerg Med Clin North Am. 2024 Feb;42(1):41-52. doi: 10.1016/j.emc.2023.06.011. Epub 2023 Sep 21.
Could dexmedetomidine be repurposed as a glymphatic enhancer?
Persson NDÅ, Uusalo P, Nedergaard M, Lohela TJ, Lilius TO.
Trends Pharmacol Sci. 2022 Dec;43(12):1030-1040. doi: 10.1016/j.tips.2022.09.007. Epub 2022 Oct 21.
Dexmedetomidine: current role in anesthesia and intensive care.
Afonso J, Reis F.
Rev Bras Anestesiol. 2012 Jan-Feb;62(1):118-33. doi: 10.1016/S0034-7094(12)70110-1.
Remimazolam: A Review in Procedural Sedation.
Lee A, Shirley M.
Drugs. 2021 Jul;81(10):1193-1201. doi: 10.1007/s40265-021-01544-8. Epub 2021 Jul 1.
Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting.
Keating GM.
Drugs. 2015 Jul;75(10):1119-30. doi: 10.1007/s40265-015-0419-5.
Procedural sedation and analgesia in children.
Krauss B, Green SM.
Lancet. 2006 Mar 4;367(9512):766-80. doi: 10.1016/S0140-6736(06)68230-5.
Remimazolam.
Teixeira MT, Goyal A.
Adv Anesth. 2024 Dec;42(1):131-150. doi: 10.1016/j.aan.2024.07.010.
Differentiating Delirium From Sedative/Hypnotic-Related Iatrogenic Withdrawal Syndrome: Lack of Specificity in Pediatric Critical Care Assessment Tools.
Madden K, Burns MM, Tasker RC.
Pediatr Crit Care Med. 2017 Jun;18(6):580-588. doi: 10.1097/PCC.0000000000001153.
Chinese medicines with sedative-hypnotic effects and their active components.
Shi MM, Piao JH, Xu XL, Zhu L, Yang L, Lin FL, Chen J, Jiang JG.
Sleep Med Rev. 2016 Oct;29:108-18. doi: 10.1016/j.smrv.2015.10.001. Epub 2015 Oct 19.
Remimazolam: First Approval.
Keam SJ.
Drugs. 2020 Apr;80(6):625-633. doi: 10.1007/s40265-020-01299-8.
